^
Association details:
| Biomarker: | MSLN expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | anetumab ravtansine (BAY 94-9343) (Microtubule inhibitor, Mesothelin-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies
Excerpt:
...Tumor response based on RECIST (Response Evaluation Criteria in Solid Tumors)`Level of mesothelin expression using IHC (Immunohistochemistry) staining for the tumor tissue obtained from fresh or archival tumor tissue`Plasma levels of soluble mesothelin`Immunogenicity evaluation based on anti-BAY94-9343 antibody count...
Trial ID:
Source:
Title:
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
Excerpt:
...- Availability of tumor tissue for mesothelin expression testing and for further biomarker analysis...
Trial ID:
More C2 evidence
Source:
Title:
Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer
Excerpt:
...- Availability of archival or fresh tissue for testing of mesothelin expression level....
Trial ID:
Source:
Title:
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
Excerpt:
...- Mesothelin expression in the tumor tissue from archival or fresh biopsy samples defined as the membrane intensity score of 2+ or 3+ (on the 0-3 scale) expressed on at least 30% of tumor cells....
Trial ID:
Source:
Title:
Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment
Excerpt:
...- Histologically or cytologically confirmed, locally advanced or metastatic solid cancers known to express mesothelin on the tumor cell surface (e.g....
Trial ID:
Source:
Title:
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Excerpt:
...- Histological documentation of malignant pleural mesothelioma (MPM) overexpressing mesothelin...
Trial ID:
Source:
Title:
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
Excerpt:
...Subjects must have histologically or cytologically confirmed previously treated unresectable mesothelin expressing advanced lung adenocarcinoma (stage IIIB or IV) as confirmed by the Laboratory of Pathology, National Cancer Institute (NCI) Subjects must have positive mesothelin expression in the archival tumor tissue, defined as the mesothelin membrane intensity score of 2+ or 3+ (on the 0-3 scale) expressed on the membrane of greater than or equal to 10% of tumor cells....
Trial ID:
Less C2 evidence
Source:
Title:
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
Excerpt:
Among 148 patients with mesothelioma or ovarian, pancreatic, non–small-cell lung, and breast cancers, 1 had a complete response, 11 had partial responses, and 66 had stable disease….Anetumab ravtansine exhibited a manageable safety and favorable pharmacokinetic profile with encouraging preliminary antitumor activity in heavily pretreated patients with mesothelin-expressing solid tumors.
DOI:
10.1200/JCO.19.02085
Trial ID:
